Drug Profile

ABP 745

Alternative Names: ABP-745; Colchicine analogue - Atom Therapeutics

Latest Information Update: 26 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Atom Bioscience
Developer Atom Therapeutics
Class Anti-inflammatories; Antigouts; Cardiovascular therapies; Colchicum alkaloids; Small molecules
Mechanism of Action Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Atherosclerosis; Gout
Preclinical Inflammation

Most Recent Events

23 Jun 2026 Pharmacodynamics data from a preclinical study in Atherosclerosis released by Atom Therapeutics
23 Jun 2026 Atom Therapeutics plans phase II trial for heart failure and pericarditis
23 Apr 2026 Phase-II clinical trials in Atherosclerosis (Treatment-experienced) in China (PO) (NCT07303777)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com